HIV/AIDS Flashcards
Key molecules of HIV replicative cycle
RT cDNA mRNA tat RnaseH gp120
tat
Protein that regulates viral Tx
Affects rate of replication
gp120
Envelope glycoprotein
1983
HIV isolated (took two years)
1987
Zidovudine available to USA
1993
AIDS leading cause of death of young adults in US
1996
HAART
Development of resistance and SE
2003
New class: fusion inhibitors
Goals of HIV Tx
Maximally inhibit viral replication Fully undetectable levels of virus Lower the viral RNA --> lower rate of accumulation of drug resistance --> longer therapeutic effect Avoid drug interactions Encourage complicance Drug combinations
General Tx strategy:
COMBINATIONS One of (NNRTI, PI, IntegraseI) + TWO NRTI
NRTIs (nucleoSide)
Zidovudine (azidothymidine or AZT)
Lamivudine
Emtricitabine
Abacavir
“Emtrici, you and Aba go feed Zido some Lami on the back Side of the house.”
NRTI (nucleoSide) mech
Competitiveliy inhibit RT
Incorporate into vDNA chain and cause termination
REQUIRES PHOSPHORYLATION by cellular enzymes to become active
Resistance to one –> resistance to another
NRTI (nucleoSide) SE
FATAL: LACTIC ACIDOSIS WITH HEPATIC STEATOSIS probably due to mitochondrial toxicity
Fat redistribution
Hyperlipidemia
Drug drug interactions
Zidovudine SE
Granulocytopenia and anemia (45% treated patients) CNS disturbances: severe HA nausea insomnia malaise
Lamivudine and Emtricitabine SE
Best tolerated of NRTIs
Abacavir SE
Hypersensitivity
NRTIs (nucleoTide)
Tenofovir
“Best ride on the Tide is a Ten*”
NRTI (nucleoTide) mech
Competitively inhibit RT
Incorporate into vDNA chain and cause termination
DOES NOT REQUIRE PHOSPHORYLATION
NRTI (nucleoTide) SE
Nausea Vomiting Diarrhea Potential for renal failure FATAL: LACTIC ACIDOSIS WITH HEPATIC STEATOSIS
NNRTIs (non-nucleoSide)
Efavirenz
Etravirine
Efa plus Etra (mobsters) kill Vir with NNRTIs (weapons)
NNRTIs mech
Bind directly to RT at side distinct from NRTI
RT can no longer produce vDNA
DOES NOT REQUIRE PHOSPHORYLATION
NO CROSS RESISTANCE WITH NRTIs or PIs
NNRTIs SE
GI intolerance
Skin rash
Drug interactions: CYP450
Efavirenz
QD CNS effects (vivid dreams, nightmares, hallucinations)
Efa: once daily gets weird dreams
Etravirine
Rash
Nausea
Peripheral neuropathy
Etra: Nausea, Neuropathy, Rash (NNRti)
Protease Inhibitors (PI)
Atazanavir
Ritonavir
Darunavir
“Darun Ate all the Rits crackers at the super bowl Party Intermission.”
PI mech
Prevents protease action required for MATURATION of fully assembled virus
*WITHOUT THIS CLEAVAGE THE VIRUS IS NOT INFECTIOUS
Prevents post-Ts cleavage of Gag-Pol polyproteins
PI SE
GI disturbances Hepatotoxicity Hyperglycemia and insulin resistance Dyslipidemia Cardiac conduction abnormalities Peripheral lipoatrophy and central fat accumulation CYP3A4 hepatic
Ritonavir boosting
high doses of PI ritonavir are POORLY TOLERATED
Used at lower doses TO INCREASE SERUM CONC OF OTHER PIS and DECREASE DOSAGE FREQ OF OTHER PIs
potent inhibitor of CYP3A4 (increases affectiveness of PIs)
Fusion Inhibitors (FI)
EnfuvirTide (T-20)
“Catching Enough (e nfu) Tides? No? Do this workout: FIT-20!”
FI mech
Binds to gp41 and prevents the conformational change necessary for fusion of viral an host cell membranes to allow virus into cell
Enfuvirtide
SubQ BID
local reactions with pain, erythema, induration, nodules, cysts
Active against other HIV-resistant antiretrovirals
Integrase Inhibitors (INSTI)
Raltegravir
“Walt’s favorite: INSTant (insti) gravy”
Ralt = Walt, gravi = gravy
INSTI mech
Binds integrase
Inhibits strand transfer, the final step of provirus integration
INSTI: integrase Strand Transfer Inhibitors
Fewer drug drug Intxns
CCR5 Antagonist
Maraviroc
CCR5/CXCR4 antagonist mech
Binds specifically and selectively to host CCR5
CCR5: receptor HIV-1 uses to get into host cell
CCR5 Ant SE
Pyrexia
Rash
Postural dizziness
HAART
Highly active antiretroviral therapy
RTIs in combo with PI
HAART associate lipodystrophy
HAART associated lipodystrophy
25-50% patients affected Wasting of suQ fat Central adiposity Hyperlipidemia, insulin resistance, diabetes mellitus Most often seen with use of NRTIs and PI
If reitonavir given in combo with darunavir, would you expect an increase, decrease, or no chance in serum conc. of daruavir computer to mono therapy with darunavir?
Would expect an increase in serum darunavir because ritonavir inhibits CYP450, which metabolizes PIs (darunavir).